Clinical Trial Update: Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and feasibility of combining bortezomib (PS-341) with interferon-alpha-2b in patients with malignant melanoma; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Interferon-alpha-2b (interferon alfa-2b)
• Velcade (bortezomib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2014-12-30